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INTRODUCTION
T-cell non-Hodgkin lymphomas (NHLs) are biologically 
diverse, uncommon malignancies that represent 
approximately 12% of all NHLs (1). T-cell NHL includes 
a spectrum of disease most recently defined in 2016, 
according to the World Health Organization (WHO)/
European Organization for Research and Treatment of 
Cancer classification (2). In the United States, cutaneous 
T-cell lymphoma (CTCL) and peripheral T-cell lymphoma 
(PTCL), not otherwise specified (NOS) are the most common 
mature T-cell NHL subtypes, accounting for 26.5% and 
15% of cases, respectively (3-5). Mature T-cell NHLs may 
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be indolent or aggressive; CTCLs are generally indolent, 
while PTCL-NOS is a “wastebasket” category of aggressive 
nodal lymphoma. Precursor T-cell lymphoblastic lymphoma 
(T-LBL) is a highly aggressive disease, representing 14% of 
lymphoblastic lymphoma typically characterized separately 
from mature T-cell NHL subtypes (5). Numerous other T-cell 
NHL subtypes have been described, each with characteristic 
histopathologic features and clinical behavior.
Imaging plays an important role in staging and 
management of many T-cell NHLs. CT is the most commonly 
used tool for staging and follow-up as it is readily available, 
easy to perform, reliable and reproducible (6). However, 
nodal involvement by CT is limited to assessment of node 
size and shape, and it may poorly depict involvement 
of bone marrow and some extranodal sites (7, 8). 
18F-flourodeoxyglucose (FDG) positron emission tomography 
CT (PET-CT) is increasingly used for staging and response 
assessment, particularly for aggressive lymphomas due 
to its superior sensitivity. PET-CT improves detection of 
extranodal involvement and accuracy of baseline staging 
compared with CT alone (9, 10). Evidence also supports 
the utility of PET-CT in treatment response assessment, 
facilitating timely optimization of appropriate treatment 
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disease may be present. In contrast to MF, SS is more 
symptomatic and is associated with lower remission and 
survival rates. 
In MF, patients with only cutaneous lesions including 
erythema, patches, and/or plaques may demonstrate no 
imaging/CT abnormalities. If the disease progresses to 
form a discrete mass, then skin thickening or a mass is 
seen on CT if one is performed (18). In the context of 
clinical trials, CT is advised when it is important to fully 
stage participants and have the ability to assess response 
(19). Repeat examinations may not be needed in patients 
with clinically early disease, while follow-up imaging is 
useful in advanced disease to detect response to treatment 
and progression, especially in terms of nodal or visceral 
involvement. PET-CT is not routinely performed in MF/
SS, though it has been shown more sensitive than CT in 
detecting nodal involvement and defining reactive versus 
malignant nodes (9, 18, 20). In one report, PET-CT was 
shown useful for more accurate measurement of skin lesion 
thickness and nodal staging, both of which have been 
correlated to outcomes (Fig. 1) (18). Imaging contributes to 
accurate staging in advanced CTCL, whereby tumor lesions 
indicate stage IIB, erythroderma in the absence of nodal or 
visceral disease indicates stage III, histologic lymph node 
involvement, irrespective of T stage represents stage IVA, 
and visceral disease represents stage IVB, irrespective of 
T and N stage. It is important to detect lymphadenopathy 
and/or other visceral organ involvement since survival rates 
decrease dramatically with visceral involvement. Pulmonary 
involvement is the most common extra-nodal involvement 
of CTCL, associated with poor outcomes (21, 22). 
Several long-term prognostic studies have revealed that 
patients with early CTCL have a favorable prognosis. In 
regimens (11, 12). Magnetic resonance imaging (MRI) is 
employed in the diagnosis and follow-up of extranodal NK/
T-cell lymphoma and subcutaneous panniculitis like T-cell 
lymphoma, due to superior soft tissue contrast in the nasal 
cavity and subcutaneous tissues, respectively (13, 14). The 
purpose of this review is to familiarize radiologists with 
clinical features and imaging manifestations of T-cell NHL 
as well as the role of CT, PET-CT and MRI in the management 
of common subtypes.
Subtypes of T-cell NHLs
Cutaneous T-cell Lymphoma 
Mycosis Fungoides/Sézary Syndrome
Mycosis fungoides (MF) and Sézary syndrome (SS) are 
the most common subtypes of CTCL, which account for 
approximately 6% of NHLs (5, 15). These entities present 
with skin involvement and are to be distinguished from 
other T-cell lymphomas which may involve the skin, to 
be discussed later (16). MF is generally indolent, and 
diagnosis is based upon clinical findings of erythematous 
patches/plaques often originating on the trunk as well as 
histopathologic findings of neoplastic CD3+ and CD4+ T-cells 
in the skin (17). Affected patients may have had several 
years of skin lesions confused with benign entities, even on 
biopsy due to accompanying non-malignant inflammatory 
infiltrates. Multiple skin biospies may be necessary for 
diagnosis. Skin lesions progress from patches to plaques to 
cutaneous tumors. SS may evolve from MF or can present de 
novo, characterized by skin rash and malignant lymphocytes 
within the peripheral blood (Sezary cells) (16). Extensive 
skin involvement, peripheral lymphadenopathy and visceral 
Fig. 1. 18FDG PET-CT in patient with cutaneous T-cell lymphoma with treatment response. 
Baseline (A) and post treatment (B) axial fused PET-CT images demonstrate abnormal skin thickening in right posterior upper thigh/inferior 
buttock with associated intense 18FDG uptake (arrows), which resolved after treatment with radiation, photochemotherapy, and topical steroids. 
FDG = flourodeoxyglucose, PET = positron emission tomography 
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fact, patients with stage IA disease may have complete 
resolution of skin lesions with treatment, which may 
include psoralen and ultraviolet A radiation, electron-beam 
radiation, topical and other treatments (16). However, 
patients with advanced CTCL have a poor prognosis despite 
intensified therapy including systemic chemotherapy. 
The extent of cutaneous involvement (ranging from T1–
T4) is significantly associated with prognosis and disease 
progression. One large study found that the risk for disease 
progression at 5 years was 10% in T1, 22% in T2, and 
48% to 56% in T3 to T4 levels of cutaneous involvement 
(23). For treatment response assessment, PET-CT can be 
used to monitor lymph nodes that are 18FDG-avid but do 
not meet the size criteria for staging (18, 24, 25). In 
addition, changes in 18FDG uptake in the form of maximum 
standardized uptake values (SUVmax) can potentially impact 
patient management (18).
At present, CTCL treatment is not based on specific 
genetic or molecular targets. However, altered molecular 
pathways and genetic drivers are being discovered and 
studied, to better understand the pathogenesis of this 
disease and to identify potential targets for treatment, 
including mutations in the T-cell receptor complex, 
nuclear factor-κB, and the Janus kinase/signal transducer 
and activator of transcription signaling pathways (26). 
Biomarkers are sought to guide management in targeted 
and non-targeted treatment settings.
Large-Cell Transformation in Cutaneous T-Cell 
Lymphoma
Mycosis fungoides may undergo a process of large cell 
transformation (LCT), which is characterized by more 
aggressive disease, in up to 39% of MF patients (Fig. 2) (27, 
28). LCT is defined histopathologically by the presence of 
large cells that are at least 4 times the size of lymphocytes 
exceeding 25% of the cell populations (29). LCT can occur 
in any stage of CTCL, however, it more frequently occurs in 
advanced stages. LCT is commonly found in skin tumors but 
may occur at any involved site, such as nodes (29). PET-
CT may be useful in patients with suspected LCT. According 
to Feeney et al. (9), average SUVmax of cutaneous lesions 
in LCT is significantly higher compared to those in MF or 
SS without LCT. The prognosis of LCT is significantly worse 
than MF. In one report, median survival of LCT patients 
from initial diagnosis of MF/SS was 37 months, compared 
with 163 months in patients with no transformation (30). 
It is recommended that any patient with MF who develops 
new papules receive a biopsy to evaluate for LCT and 
subsequent PET-CT. If LCT is confirmed, patients are treated 
more aggressively, with systemic chemotherapy and possibly 
autologous or allogeneic hematopoietic cell transplantation 
(HCT) and/or radiation (29).
Peripheral T-Cell Lymphoma, Not Otherwise Specified 
Peripheral T-cell lymphoma, NOS is a heterogeneous group 
of predominantly nodal T-cell lymphomas. It is the most 
common subtype of PTCL, accounting for approximately 
30% of PTCL and approximately 4% of NHLs overall (5). 
PTCL NOS is usually aggressive and relapse is common. Most 
patients present with generalized lymphadenopathy with 
or without extra-nodal disease, including involvement of 
skin, gastrointestinal tract, liver, spleen or marrow (31-
Fig. 2. Contrast-enhanced CT and 18FDG PET-CT in patient with transformed cutaneous T-cell lymphoma. 
Axial contrast-enhanced CT image (A) demonstrates diffuse skin thickening in left groin (arrows), which resolved following treatment with 
radiation, phototherapy, and Targretin (not shown). Unfortunately, on subsequent restaging contrast-enhanced chest CT (B), patient developed 
bilateral pulmonary masses (arrows), which were biopsy proven cutaneous T-cell lymphoma. As seen on axial fused PET-CT image (C), pulmonary 
lesions increased in size and number despite treatment with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) regimen 
(arrow), pralatrexate, gemcitabine, Ontak, allogenic stem cell transplant, and palliative radiation and patient eventually expired from pulmonary 
complications. FDG = flourodeoxyglucose, PET = positron emission tomography 
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Fig. 3. 18FDG PET-CT in patient with peripheral T-cell lymphoma, not otherwise specified with treatment response. 
Baseline MIP (A) and axial fusion (B) PET-CT images demonstrate intense 18FDG uptake in left neck corresponding with large soft tissue mass 
and intense 18FDG uptake in left base of tongue (arrows). Additional sites of 18FDG uptake are seen in upper paratracheal region, inguinal 
stations, and right thigh (arrowheads). Post treatment MIP (C) and axial fusion (D) images following treatment with RCHOP and neck radiation 
demonstrate resolution of 18FDG uptake and soft tissue mass. FDG = flourodeoxyglucose, MIP = maximum intensity projection, PET = positron 
emission tomography 
A
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35). Approximately 60% of patients with PTCL NOS have 
stage IV disease at the time of diagnosis (35). Diagnosis 
of PTCL NOS is made based upon the results of a tissue 
biopsy, usually of a lymph node. However, because PTCL 
NOS is essentially a diagnosis of exclusion, the diagnostic 
agreement rate among expert hematopathologists in one 
report was only about 75% (33). Gene expression profiling 
studies have identified subtypes of PTCL NOS with differing 
clinical behavior and response to therapy (2, 36). 
On CT, generalized lymphadenopathy is the most 
common finding in PTCL NOS. The imaging appearance 
is generally not distinguishable from other types of 
lymphoma. On PET-CT, PTCL NOS is often 18FDG-avid, as 
seen in 33 of 34 patients in one report with SUVmax ranging 
from 2.8 to 42.3 (mean 12.3) (Fig. 3) (9). According to 
the Lugano classification guidelines, which are the most 
recent recommendations for initial evaluation, staging, 
and response assessment of Hodgkin and NHL, PET-CT is 
recommended for routine staging of 18FDG-avid, nodal 
lymphomas (37). It may become more commonly used in 
PTCL NOS.
The standard treatment for PTCL NOS is a conventional-
dose systemic anthracycline-containing chemotherapy 
(3). The role of HCT is still investigational and the 
potential benefit of HCT is difficult to ascertain due to 
reports combining PTCL subtypes and disease rarity (38). 
Poor prognostic factors in PTCL NOS include age > 60, 
performance status ≥ 2, elevated lactate dehydrogenase 
(LDH) and bone marrow involvement (39). According to one 
multicenter study, the cumulative 5-year overall survival 
of PTCL NOS was 43% (39). Attempts have been made to 
identify biologically and prognostically distinct subgroups 
within the heterogeneous PTCL NOS category. For example, 
Epstein-Barr virus (EBV) is found in approximately 30% of 
all cases of PTCL NOS and may be associated with a more 
aggressive course (40). 
Angioimmunoblastic T-Cell Lymphoma
Angioimmunoblastic T-cell lymphoma (AITL) is a rare 
subtype of PTCL, which accounts for 1–2% of NHLs and 
15–20% of PTCLs (3). It is more common in elderly, and 
patients often present with an acute onset systemic illness 
Fig. 4. 18FDG PET-CT and diagnostic contrast-enhanced chest CT in patient with angioimmunoblastic T-cell lymphoma. 
MIP image (A) demonstrates intense 18FDG uptake in cervical, thoracic, abdominal, and left inguinal lymph node stations, subcutaneous nodules, 
and bilateral pulmonary nodules, masses, and consolidations. Focal 18FDG uptakes in left arm are likely related to injection. Axial fused PET-
CT image (B) demonstrates intense 18FDG uptake right axillary lymphadenopathy (arrow) and within bilateral pulmonary nodules and masses. 
Axial contrast-enhanced CT image on lung window (C) demonstrates pulmonary nodules and masses with surrounding groundglass opacities and 
mild intralobular septal thickening. One of lung masses was biopsied, and proven to be angioimmunoblastic lymphoma. Patient had complete 
response after treatment with CHOP and underwent autologous stem cell transplant but developed myelodysplastic syndrome and T-cell lymphoma 
recurrence and expired. FDG = flourodeoxyglucose, MIP = maximum intensity projection, PET = positron emission tomography 
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including B symptoms, generalized lymphadenopathy, 
and hepatosplenomegaly at the time of diagnosis. The 
CT features are nonspecific and similar to those of any 
disseminated lymphoma. The lesions usually exhibit high 
18FDG avidity (Fig. 4) (41). AITL is generally an aggressive 
disease, although occasional spontaneous remissions 
are seen. Relapse is frequent and overall survival is low, 
reportedly 32% in one report (42). 
Anaplastic Large Cell Lymphoma, Primary Systemic Type
In the WHO classification, systemic anaplastic large cell 
lymphoma (ALCL) can be divided into two subgroups on 
the basis of the expression of anaplastic lymphoma kinase 
(ALK) protein. ALK-positive ALCL is characterized by a 
chromosomal translocation linking the ALK kinase gene on 
chromosome 2 to the nucleophosmin gene on chromosome 
5, resulting in a constitutively active tyrosine kinase 
(43). The distinction of ALK-positive and ALK-negative 
ALCL is important because of clinical and prognostic 
differences. Namely, ALK-positive ALCL is more common 
in younger patients who generally have superior outcomes 
when treated with standard chemotherapy as compared to 
patients with ALK-negative ALCL (43). ALK-positive ALCL 
patients typically have 5-year overall survival rates of more 
than 70%, whereas patients with ALK-negative ALCL have 
5-year overall survival rates less than 50% (43, 44). 
Patients with ALCL often present with painless 
lymphadenopathy, with or without extra-nodal involvement 
(Fig. 5). One study has shown differences in extra-
nodal sites involved in ALK-positive and ALK-negative 
ALCLs: bone marrow, bone, subcutaneous tissue, and 
splenic involvement were seen at more commonly in ALK-
positive patients, whereas skin, liver, and gastrointestinal 
involvement was more frequent in ALK-negative ALCL (43). 
The degree of 18FDG uptake is higher in ALK- positive ALCL 
than in ALK-negative ALCL, suggesting that PET may be 
useful in distinguishing between the two groups (45).
Extranodal NK/T-Cell Lymphoma
Extranodal NK/T-cell lymphoma is most common in Asia 
and in native populations of Central and South America, 
and it is rare in the United States and Europe (3, 46). It is 
Fig. 5. 18FDG PET-CT in patient with anaplastic large cell lymphoma with treatment response. 
Baseline CT (A) and PET (B) images demonstrate intense 18FDG uptake within left external iliac and pelvic sidewall lymphadenopathy (arrows). 
Post treatment CT (C) and PET (D) images demonstrate complete resolution of lymphadenopathy and 18FDG uptake after treatment with CHOP. 
FDG = flourodeoxyglucose, PET = positron emission tomography 
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strongly associated with EBV infection. 60–80% patients 
present with localized disease involving aerodigestive 
tract, resulting in symptoms of nasal obstruction, epistaxis 
and/or destructive mass involving the nasal cavity, 
sinuses or oral cavity (47). Lymph nodes may be involved 
secondarily but are rarely the primary site of involvement. 
Extranasal involvement is common in soft tissues/skin, 
the gastrointestinal tract, lungs, adrenal glands, testes or 
central nervous system (CNS) (47). Extranasal extranodal 
NK/T-cell lymphoma is associated with more aggressive 
features in terms of advanced stage at presentation, poorer 
performance status of affected patients, inferior response to 
chemotherapy and poorer survival (47, 48). 
On CT, tumors show soft tissue attenuation with mild 
to moderate heterogeneous enhancement. MRI is better 
demonstrating the extent of lesion as compared to CT, 
especially in the nasal type (Fig. 6) (49). Signal intensity 
of tumors is higher than that of muscle but lower than that 
of sinonasal mucosa on T2-weighted spin-echo images. 
On T1-weighted spin-echo images, tumors show similar 
to higher signal intensity than that of muscle. PET-CT is a 
useful tool for initial diagnosis and staging, because both 
nasal and extranasal lesions exhibit high 18FDG avidity 
(Fig. 7) (41, 50, 51). Radiotherapy has been validated as 
primary treatment for localized nasal NK/T-cell lymphoma 
in several large retrospective studies (52-56). As expected, 
patients with early stage disease have a better prognosis as 
compared to patients with advanced disease.
 
Subcutaneous Panniculitis Like T-Cell Lymphoma
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) 
is a rare subtype of peripheral T-cell lymphoma, accounting 
for less than 1 percent of all NHLs (3). Patients with SPTCL 
typically present with one or more usually painless nodules 
or poorly circumscribed indurated plaques most commonly 
located on the trunk or lower extremities (57, 58). Initial 
diagnosis of SPTCL is often delayed because inflammatory 
or infectious processes may be suspected both clinically 
and on imaging. MRI features of SPTCL include nodular or 
mass-like enhancing areas that infiltrate the subcutaneous 
tissues (Fig. 8) (14). Central areas of intermediate T2-
weighted signal intensity (compared to muscle) may be 
seen, which can be useful in differentiating SPTCL from 
other inflammatory or infectious processes (14). Both 
CT and PET-CT are useful for recognizing other organ 
involvement and evaluating the extent of disease (40, 59). 
Whole body MRI has also been suggested as a useful tool 
at initial diagnosis and follow-up, to assess the extent of 
disease and monitor a patient’s response to therapy (60). 
The clinical course of SPTCL can be indolent with relapsing 
panniculitis, or aggressive with the development of a 
hemophagocytic syndrome which can be fatal. Favorable (αβ) 
Fig. 6. MRI and 18FDG PET-CT in patient with extranodal natural killer T-cell lymphoma of nasal cavity. 
Axial T2-weighted MR image (A) shows diffuse thickening of right nasal mucosa with T2-hypointensity (arrows) compared to left side. Axial 
fused PET-CT image (B) demonstrates corresponding intense 18FDG uptake in right nasal cavity (arrows). FDG = flourodeoxyglucose, PET = positron 
emission tomography
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and poor (γδ) prognostic phenotypes have been described 
(57).
Precursor T-Cell Lymphoblastic Lymphoma 
Precursor T-cell lymphoblastic lymphoma is a rare but 
highly aggressive neoplasm of lymphoblasts of T-cell origin, 
with an incidence of approximately 2% of adult NHLs. 
Patients are commonly young adults who may present 
with lymphadenopathy in the cervical, supraclavicular, 
and axillary regions and/or bulky mediastinal masses 
(Fig. 9) (61-63). Superior vena cava syndrome, tracheal 
obstruction and pleural and/or pericardial effusions may 
be associated (64). Extranodal disease (e.g., involvement 
of the skin, testis, liver, spleen and/or bone) is a less 
common presentation. Central nervous system involvement 
more commonly occurs in patients with bone marrow 
involvement.
Imaging studies such as total body CT scan (head and 
neck, thorax, abdomen, and pelvis) and PET-CT are used 
for staging and therapeutic response evaluation. For 
post induction response assessment, CT scan is useful 
for evaluation of intrathoracic and abdominal disease 
involvement. Mediastinal mass assessment is important in 
T-LBL, as residual masses can remain after treatment and 
mediastinal relapses can occur. Most T-LBL exhibit high 
18FDG avidity on PET-CT at baseline, prior to the start of 
treatment (9, 40, 62, 64). Although PET did not predict 
long-term outcome in previous retrospective studies (65, 
Fig. 7. 18FDG PET-CT in patient with extranodal natural killer T-cell lymphoma. 
MIP (A) and axial fused PET-CT (B) images demonstrate intense 18FDG uptake in left lower extremity, involving marrow compartment of distal 
left tibia and surrounding subcutaneous soft tissue and overlying skin medially (arrows). FDG = flourodeoxyglucose, MIP = maximum intensity 
projection, PET = positron emission tomography 
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66), PET-negativity is useful because it may eliminate the 
need for intensification of chemotherapy or mediastinal 
irradiation. 
A variety of therapeutic approaches in T-LBL have been 
reported, including chemotherapy protocols for high 
grade NHL and HCT. Complete response rates of greater 
than 80% and a disease-free survival rate of 56% have 
been reported in adults treated with intensive/acute 
lymphoblastic leukemia-type regimens (61, 67, 68). While 
prognostic models are not yet defined for adult T-LBL, poor 
risk features in adults include age > 30 years, advanced 
stage III or IV disease, high LDH level (more than 1.5 
times normal), involvement of central nervous system, 
bone marrow or mediastinum (67, 69, 70). Patients with 
Fig. 8. Contrast-enhanced MRI in patient with subcutaneous panniculitis-like T-cell lymphoma. 
Axial T2 fat-sat (A) and T1-weighted (B) images demonstrate vague areas of increased T2 hyperintensity and T1 isointensity in subcutaneous 
tissues of posterior proximal thighs (arrows). Axial T1-weighted postcontrast (C) image demonstrates corresponding areas of enhancement 
(arrows). 
A
C
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Fig. 9. 18FDG PET-CT images in patient with precursor T-cell lymphoma with treatment response. 
Baseline axial fused PET-CT image (A) demonstrates large hypo to isodense anterior mediastinal mass with mild to moderate 18FDG uptake (arrows). 
Post treatment axial fused PET-CT image (B) show resolution of anterior mediastinal mass and abnormal 18FDG uptake following treatment with 
Larson protocol intensification. FDG = flourodeoxyglucose, PET = positron emission tomography 
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Fig. 10. Contrast-enhanced chest CT in patient with precursor T-cell lymphoma with surgical resection. 
Baseline axial CT image (A) demonstrates large heterogeneously enhancing anterior mediastinal mass with associated pericardial effusion (arrows) 
and bilateral pleural effusions. Patient was taken for urgent pericardial window procedure, biopsy, which was initially thought to represent 
thymoma. Patient was treated with urgent radiation, chemotherapy with cytoxan, adriamycin, and cisplatin, and eventual surgical resection 
showing no residual disease in specimen, which was thought to be unusual for thymoma. Postsurgical axial CT image (B) demonstrates mild 
stranding in anterior mediastinum, consistent with postsurgical changes, without evidence for residual or recurrent lymphoma. Re-review of 
initial biopsy was felt to represent precursor T-cell lymphoma. Patient underwent induction chemotherapy per CALGB 9111 protocol and stem cell 
transplant. Following stem cell transplant, patient unfortunately developed veno-occlusive disease, as seen on ultrasound color Doppler images 
showing reversal of flow in right (C) and main (D) portal veins and expired despite transjugular intrahepatic portosystemic shunt procedure 
(arrowheads) (E).
A
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poor risk features are potential candidates for intensified 
therapy and HCT (14, 68). Song et al. (71) achieved higher 
event free survival and overall survival in T-LBL patients 
who proceeded to HCT compared to patients treated with 
chemotherapy alone. Disease relapse has been reported as 
a leading cause of death after HCT, followed by infections, 
graft-versus-host disease, respiratory, cardiovascular and 
other treatment-associated complications (Fig. 10) (72, 
73).
CONCLUSION
T-cell NHLs include a wide spectrum of diseases ranging 
from indolent to highly aggressive, associated with varied 
clinical features and prognosis. It is important to have 
familiarity with common subtypes of T-cell NHL, including 
the expected clinical courses and prognostic factors, to 
best interpret imaging studies and guide management in 
affected patients. Specifically, cutaneous disease is often 
indolent; nodal and/or visceral involvement indicates the 
need for more aggressive treatment. PTCL NOS is a common 
subtype, often aggressive. Precursor T-LBL is aggressive, 
with poor prognosis. Imaging studies including CT, MRI 
and PET-CT have important and specific roles in the 
various entities, not only for staging but also in response 
assessment and detection of disease-related and treatment-
related complications. 
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